PSTX Poseida Therapeutics Inc

Price (delayed)

$3.38

Market cap

$327.72M

P/E Ratio

N/A

Dividend/share

N/A

EPS

-$1.18

Enterprise value

$358.98M

Poseida Therapeutics is a clinical-stage biopharmaceutical company dedicated to utilizing its proprietary genetic engineering platform technologies to create next generation cell and gene therapeutics with the capacity to cure. Poseida ...

Highlights
Poseida Therapeutics's debt has decreased by 3.8% YoY
Poseida Therapeutics's net income has plunged by 143% YoY but it has increased by 12% from the previous quarter
PSTX's EPS has shrunk by 82% YoY but it is up by 14% QoQ
The quick ratio has dropped by 53% year-on-year and by 20% since the previous quarter
Poseida Therapeutics's equity has decreased by 46% YoY and by 18% QoQ

Key stats

What are the main financial stats of PSTX
Market
Shares outstanding
96.96M
Market cap
$327.72M
Enterprise value
$358.98M
Valuations
Price to earnings (P/E)
N/A
Price to book (P/B)
3.86
Price to sales (P/S)
3.93
EV/EBIT
N/A
EV/EBITDA
N/A
EV/Sales
4.35
Earnings
Revenue
$82.5M
EBIT
-$99.85M
EBITDA
-$94.18M
Free cash flow
-$71.71M
Per share
EPS
-$1.18
Free cash flow per share
-$0.75
Book value per share
$0.88
Revenue per share
$0.86
TBVPS
$2.68
Balance sheet
Total assets
$262.58M
Total liabilities
$177.99M
Debt
$84.56M
Equity
$84.59M
Working capital
$131.97M
Liquidity
Debt to equity
1
Current ratio
2.56
Quick ratio
2.49
Net debt/EBITDA
-0.33
Margins
EBITDA margin
-114.2%
Gross margin
100%
Net margin
-131.9%
Operating margin
-138.9%
Efficiency
Return on assets
-38.9%
Return on equity
-97.4%
Return on invested capital
-40.6%
Return on capital employed
-56.2%
Return on sales
-121%
Dividend
Dividend yield
N/A
DPS
N/A
Payout ratio
N/A

PSTX stock price

How has the Poseida Therapeutics stock price performed over time
Intraday
0.6%
1 week
13.8%
1 month
22.46%
1 year
77.89%
YTD
0.6%
QTD
15.75%

Financial performance

How have Poseida Therapeutics's revenue and profit performed over time
Revenue
$82.5M
Gross profit
$82.5M
Operating income
-$114.56M
Net income
-$108.86M
Gross margin
100%
Net margin
-131.9%
The operating income has dropped by 170% year-on-year but it is up by 12% since the previous quarter
Poseida Therapeutics's net income has plunged by 143% YoY but it has increased by 12% from the previous quarter
The revenue has contracted by 41% YoY but it has grown by 28% from the previous quarter
The gross profit has contracted by 41% YoY but it has grown by 28% from the previous quarter

Growth

What is Poseida Therapeutics's growth rate over time

Valuation

What is Poseida Therapeutics stock price valuation
P/E
N/A
P/B
3.86
P/S
3.93
EV/EBIT
N/A
EV/EBITDA
N/A
EV/Sales
4.35
PSTX's EPS has shrunk by 82% YoY but it is up by 14% QoQ
The P/B is 60% more than the last 4 quarters average of 2.4
Poseida Therapeutics's equity has decreased by 46% YoY and by 18% QoQ
The revenue has contracted by 41% YoY but it has grown by 28% from the previous quarter
The stock's price to sales (P/S) is 15% more than its last 4 quarters average of 3.4

Efficiency

How efficient is Poseida Therapeutics business performance
The ROIC has shrunk by 188% YoY but it is up by 3.6% QoQ
PSTX's ROA has dropped by 172% year-on-year but it is up by 8% since the previous quarter
PSTX's ROS is up by 32% QoQ
PSTX's ROE is down by 2.6% since the previous quarter

Dividends

What is PSTX's dividend
DPS
N/A
Dividend yield
N/A
Payout ratio
N/A

There are no recent dividends present for PSTX.

Financial health

How did Poseida Therapeutics financials performed over time
The total assets is 48% more than the total liabilities
The quick ratio has dropped by 53% year-on-year and by 20% since the previous quarter
The current ratio has plunged by 52% YoY and by 19% from the previous quarter
Poseida Therapeutics's debt to equity has surged by 79% YoY and by 22% QoQ
Poseida Therapeutics's equity has decreased by 46% YoY and by 18% QoQ

All financial data is based on trailing twelve months (TTM) periods - updated quarterly, unless otherwise specified.